In vitro neurology assays
Screen your lead candidate compounds using InnoSer’s in vitro neurology assays to progress to preclinical in vivo studies with confidence
InnoSer’s Neurodegenerative in vitro Assays CRO Services:
In vitro neurology assays are carried out using primary and/or immortalized rodent and/or human (co)-cultures to screen and identify candidate compounds for further lead selection via preclinical in vivo research. Cultures of cells found within the central nervous system (CNS) such as microglial and neuronal cells allow you to evaluate the mechanism of action and efficacy of your novel investigational compounds in an in vitro setting for neurotoxicity, neurodegeneration/neuroprotection or neuroinflammation assessment.
InnoSer offers preclinical contract research services using a wide range of commercially available cell lines, as well as primary rodent cells. Leverage our validated in vitro neurodegeneration assays or partner with our scientists to set up and validate custom assays. After an initial disease model induction phase (using disease-associated proteins, protein aggregates. and chemical toxins), cell cultures are treated with your novel investigational compounds of choice to determine efficacy. In vitro neurodegenerative disease assays can be performed before or in conjunction with running in vivo preclinical studies (PK/PD profiling or efficacy studies in InnoSer’s mouse models of neurodegenerative diseases).
✓ Wide range of neurology in vitro assays in (co)-cultures of rodent primary cells, as well as immortalized rodent and human cell lines of neuronal and microglial cells (e.g. SHSY5Y, HCM3).
✓ Neurodegenerative disease-associated proteins, chemical induction of disease phenotype, or transgenic cell lines.
✓ Wide range of assays (e.g., aggregation, phagocytosis, neurotoxicity, and neuroinflammation).
✓ Custom model and assay validation services available.
Developing new, safe, and efficacious therapies is an extremely intricate process. As a preclinical neurology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical neurology studies to InnoSer, you gain access to our in vitro and in vivo neurology drug development portfolio.
あなたの神経学研究はここから始まります。
自信を持って研究に適したモデルを選択する
Example data featuring in vitro neurology assays:
The human neuroblastoma cell line SH-SY5Y serves as an excellent in vitro model for evaluating a compound’s ability to rescue neurodegenerative disease phenotypes marked by significant ROS production induced by disease-related peptides.
Treating neuronal cells (SH-SY5Y) with amyloid-beta Aβ fibrils leads to increased ROS production, which can be rescued by co-treatment with Edaravone (3 hours after treatment (*P<0.05; ****P<0.0001).
The Aggregation assay confirms Aβ-42 fibril aggregation kinetics in vitro, confirming the fibrils suitability in subsequent assays.
The formation of fibril aggregates is monitored by fluorescence resulting from binding of Thioflavin T (ThT) to the aggregates. 24-hour incubation of Aβ–fibrils with the reporter ThT (20 μM) leads to significant increases in Aβ-42 fibril aggregation (*P<0.05; **P<0.01).
The Aβ-induced phagocytosis assay can be used to test novel Alzheimer’s disease compounds’ efficacy in stimulating the clearance of Aβ fibrils.
Aβ-42 fibril treatment induces significant increase in HMC3 cells’ phagocytic capacity in comparison to no fibril treatment. Simultaneous treatment of 0.1 µg/ml Aducanumab and 5.0 µM fibrils induces a significant increase in phagocytic capacity in comparison to 5.0 µM fibril treatment alone (*P<0.05, **P<0.005, ***P<0.001, ****P<0.0001).
The Aβ-induced and ⍺–synuclein-induced neurotoxicity in vitro assay can be used to test novel Alzheimer’s and Parkinson’s disease compounds’ efficacy in rescuing cell viability.
24-hour treatment with Aβ–42 and ⍺-synuclein fibrils induces toxicity in SH-SY5Y and HMC3 cells compared to the control condition (**P=0.005; ***P=0.001; ****P<0.0001).
あなたの神経学研究はここから始まります。
Here, we present validated cellular models to enable efficient screening of disease-modifying candidate compounds for Alzheimer’s and Parkinson’s diseases prior to, or in conjunction with, in vivo screening.
In vitro neurology assays
Neurodegenerative disease in vitro modelling
Model neurodegenerative diseases using the following methods:
- Disease-related peptides (e.g., amyloid-β fibrils, MBP, α-synuclein, etc.)
- Stimulus–induced (e.g., LPS, IL-13, Rotenone, etc.)
- Neurotoxins (e.g., H2O2, 6-OHDA, Rotenone, etc.)
あなたの研究を支える人々
ソフィー・カーマンス博士
主任神経科学研究員
トーマス・フォーゲルス博士
主任神経科学研究員
治療薬を血液脳関門を通過させるのに苦労していませんか？
SonoCloud®超音波媒介型血液脳関門（BBB）破壊技術が、化合物を変更することなく脳内取り込みを改善する仕組みをぜひご覧ください。
その他の関連疾患モデルを発見する
好奇心を持ち続けよう：さらに探求できる記事
Clinically relevant biomarker panels for comprehensive efficacy studies in Alzheimer’s Disease mouse models
InnoSer's validated Alzheimer's disease (AD) mouse models are equipped with translationally relevant biomarker readout panels — spanning amyloid-beta (Aβ) species, phosphorylated Tau isoforms, and the early, sensitive hallmark of neurodegeneration, neurofilament light...
![Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)
Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept
The Tau[P301S] mouse remains one of the most established in vivo models for evaluating therapeutics targeting tauopathies including Alzheimer's disease and frontotemporal dementia (FTD). Presented at AD/PD 2025 in Vienna, this poster provides comprehensive...
Home-Cage Behavior Discriminates Neurodegeneration Models from Healthy Aging Mice
Distinguishing pathological neurodegeneration from normal biological aging is a fundamental challenge in preclinical neuroscience. Presented at AD/PD 2023 in Gothenburg, this poster — developed in collaboration with Sylics and VU University Amsterdam — establishes a...
Early Phenotypic Characterization of TDP-43 Q331K Mouse Model of ALS Reveals Elevated Plasma Neurofilament Light, Nerve Conduction Abnormalities and Behavioral Deficits
TDP-43 pathology underlies 97% of all ALS cases, making the TDP-43(Q331K) transgenic mouse a clinically relevant preclinical tool. Presented at SfN Neuroscience 2025 in San Diego, this poster provides longitudinal phenotypic characterization of female TDP-43(Q331K)...
AAALAC認定
InnoSerはAAALAC認証を取得し、責任ある動物ケアと利用への取り組みを実証しています。AAALAC Internationalは、自主的な認証および評価プログラムを通じて科学における動物の適切な扱いを推進する非営利組織です。InnoSerのオランダおよびベルギー施設は、それぞれ2016年および2020年よりAAALAC認証を取得しています。AAALAC認証プログラムの詳細はこちらをご覧ください。
動物福祉
3R原則は、政策や規制の変更から新技術・手法の開発と普及に至るまで、あらゆる分野に影響を及ぼします。このためInnoSerは、これらのプロセスに対する継続的な取り組みと監視を実施しています。当社が実践する手順は、動物実験の代替・削減・改善を最大限に実現し、研究および医薬品開発におけるこれらの原則への取り組みを促進します。
info@innoserlaboratories.com